Navigation Links
WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release

SHANGHAI, Oct. 28 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the third quarter of 2009 after the New York Stock Exchange closes on Monday, November 16, 2009 (which will be Tuesday morning, November 17, 2009 Shanghai time).

(Logo: )

The earnings release will be available on the investor relations section of its website at .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, November 17, 2009, to discuss the third-quarter 2009 financial results and recent business activities. The conference call may be accessed by calling:

        United States:    1-866-519-4004
        China (Landline): 800-819-0121
        China (Mobile):   400-620-8038
        Hong Kong:        800-930-346
        United Kingdom:   0-808-234-6646
        International:    +65-6735-7955
        Conference ID:    38748238

    A telephone replay will be available two hours after the call's completion

        United States:    1-866-214-5335
        China North:      10-800-714-0386
        China South:      10-800-140-0386
        Hong Kong:        800-901-596
        United Kingdom:   0-800-731-7846
        International:    +61-2-8235-5000
        Conference ID:    38748238

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048


SOURCE WuXi PharmaTech (Cayman) Inc.

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech to Participate in Upcoming Investor Conferences
2. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
3. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
4. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
5. WuXi PharmaTech Announces First-Quarter 2009 Results
6. WuXi PharmaTech Appoints Hao Zhou as Vice President of Finance
7. Pharmatech Oncology Launches New Data Management Business Unit
8. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
9. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
10. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
11. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
Post Your Comments:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: